1 / 25

Binu George , Heather Bury Critical care Journal Club May 2014

Effect of Levosimendan on the Short-Term Clinical Course of Patients With Acutely Decompensated Heart Failure. Binu George , Heather Bury Critical care Journal Club May 2014. Background. Over a million people hospitalised in the US for treatment of ADHF

pascha
Télécharger la présentation

Binu George , Heather Bury Critical care Journal Club May 2014

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Effect of Levosimendan on theShort-Term Clinical Course of Patients With Acutely Decompensated Heart Failure Binu George , Heather Bury Critical care Journal Club May 2014

  2. Background • Over a million people hospitalised in the US for treatment of ADHF • Usually receive IV diuretics , peripheral vasdilators ,positive inotropes • Unclear how haemodynamics translate to clinical benefits • Average hospital stay 5 days

  3. Methods • REVIVE 1 and 2 carried out in 103 centres in the US, Australia and Israel between December 2001 and December 2004 • All patients with ADHF who remained dyspneic inspite of treatmet with intravenous diuretics

  4. Study Plan • Randomly assigned (double blind) to treatments with placebo or levosimendan which was added to their existing treatment plan • Study endpoints- composite of clinically relevant measures

  5. Outcome measurement • Primary end point in both trials -clinical course during first 5 days characterized as improved , unchanged or worse. • Secondary endpoint- BNP at 24 hrs ,changes in global assessment at 6hrs ,changes in perception of dyspnoea at 6hrs ,numer of days alive (1-14 days after randomization),NHYA functional status at day 5,all cause mortality during first 90 days

  6. Worsening clinical status requiring rescue therapy in revive 1 and 2

  7. Results • 12% of levosimendan group and 7% of placebo group discontinued before 24 hrs • Primary endpoints- patients improved on levosimendan compared to placebo • In both groups no differences in groupsin number of days alive over 14 days

  8. Results • Levosimendan arm briefer hospital stays-46%vs37% • NYHA functional status was not significantly different between both groups • Safety- higher number of adverse effects with levosimendan

  9. discussion • Robust study , demonstrates favourable effect on short term clinical course of patients with ADHF • Likely reason for incresed mortality in levosimendan arm due to increased used of loading dose and approach which is no longer followed

  10. Levosimendan • Mode of Action • Calcium sensitisation • Increased cardiac contractility • K+ ATP channel opening • Pharmacokinetics • Onset of action: 1 minute • Half life 1 hour • Excreted in faeces and urine • Prolonged haemodynamic effects

  11. Levosimendan effects…. • Cardioprotective effect • Anti inflammatory effect • Neurohormonal effect • Improves coronary circulation • Antistunning effect • Haemodynamic effects

  12. LIDO Study • Multicenter ,double blind,double dummy.randomized study • Designed to compare clinical and haematological effects of levosimendan vs Dobutamine in low output heart failure • 203 patients- levosimendan improved haemodynamic performance and decreased mortality for upto 180 days

  13. RUSSLAN TRIAL • Double blind placebo controlled • Evaluating different doses of levosimendan vs placebo in patients with heart failure secondary to MI • 504 patients – higher dose , greater side effects • Overall mortality better than placebo group (at 14 days)

  14. CASINO TRIAL • Randomised , double blinded, double dummy and parallel group study • 299 patients NYHA 4 (LVEF less than 35%) • Stopped prematurely – significant survival benefit with levosimendan compared with dobutamine

  15. SURVIVE TRIAL • Randomized ,double blind, double dummy, prospective controlled study • 1327 patients (LVEF-less than 35%)- not responding to IV diureticsand vasodilator therapy • Primary endpoint- all cause mortality in 180 days – no statistical difference • 25% lower mortality compared to dobutamine 6 hrs,24 hrs , 5,14,30 days

  16. Levosimendan Facts !! • Well tolerated • Side effects – headache ,hypotension,dizzyness,nausea • Can cause VT ,AF at higher doses • Recommended dose 6-24 μg/kg/min administerted in 10-20 min and maintainance dose- 0.05-0.2 μg/kg/min over 24 hrs

  17. Facts !! • Not licensed for use in the UK and USA however still used • Not recommended for use in patients with Bp less than 90 systolic • Can be used in conjunction with betablockers, noradrenaline • Can also be used in septic shock (some proven benefit)

  18. Discussion • New inodilator agent for therapy in end stage heart failure • Proven benefits compared to dobutamine • Further trials may help clarify its effects on mortality and use in clinical practice

  19. Any Questions ???

  20. Thank You !!

More Related